Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics (SCORE-Peds)

March 25, 2026 updated by: Intermountain Health Care, Inc.

The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. The main questions it aims to answer are:

  • How can a large healthcare system drive high adherence to antibiotic stewardship across a large and diverse number of sites?
  • How do determinants of implementation and needed strategies vary by context?
  • What is the utility of a higher-resource implementation effort (named "Boost) focusing on outlier sites?

Data will be collected on number of children reached, adherence changes over time, types of implementation strategies employed, and characteristics of sites, prescribers, and patients.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

259000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Utah
      • Murray, Utah, United States, 84107
        • Intermountain Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All children meeting eligibility criteria and treated at any facility within the Intermountain region specified (wave 1 & wave 2) between January 1, 2026 and December 31, 2028.

Description

Inclusion Criteria:

  • Age 6 months through 17 years
  • ARTI diagnosis (acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP))

Exclusion Criteria:

  • Age <6months or >18 years
  • No ARTI diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Children with ARTIs, Wave 1
Children under 18 treated in Wave 1 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP)
Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
o facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training & education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation.
Children with ARTIs, Wave 2
Children under 18 treated in Wave 2 of antibiotic stewardship for the following conditions: acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP)
Other: Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation
o facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training & education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic Prescribing
Time Frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Rates of narrow-spectrum antibiotic (AB) prescriptions as a proportion of all antibiotics prescribed in aggregate and within each of these diagnoses: Acute otitis media, Group A streptococcal pharyngitis, Acute sinusitis, and Pneumonia.
Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Guideline-adherent Duration of Antimicrobial Therapy
Time Frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Rate of AB prescriptions with guideline-adherent number of days prescribed as proportion of all AB prescriptions in aggregate and for each of the target ARTI diagnoses.
Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Treatment Failure
Time Frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Clinical encounter for the same diagnosis between 2 and 14 days following the index encounter and receipt of an alternative antibiotic for the same respiratory diagnosis during the return visit.
Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Staff): Adherence to Protocols
Time Frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Number and proportion of prescribers who are "adherent" to guideline-based prescribing protocols for Broad vs. Narrow Spectrum AB Prescribing, and Duration.
Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation
Adoption (Organization): Adherence to Protocols
Time Frame: Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.
Number and proportion of sites where 60% of prescribers are adherent.
Baseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Intermountain Health Care, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2026

Primary Completion (Estimated)

January 15, 2029

Study Completion (Estimated)

January 15, 2029

Study Registration Dates

First Submitted

December 31, 2025

First Submitted That Met QC Criteria

December 31, 2025

First Posted (Actual)

January 12, 2026

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 25, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HSII_IHC_IMP-PS2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This is an implementation study using observational data with a waiver of consent. Therefore, there is no consent to allow for the sharing of IPD.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Antibiotic

Clinical Trials on Implementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe